|
Home : Unsafe Drugs : Avandia : Newsfeeds : Oramed Successfully Completes Toxicity Study For ORMD-0801 Oramed Successfully Completes Toxicity Study For ORMD-0801
Oramed Pharmaceuticals Inc. (OTC: ORMP), a developer of oral delivery systems, announced today that it has successfully completed a comprehensive toxicity study for its flagship oral insulin capsule, ORMD-0801. The study was completed under conditions ...
Avandia Case Evaluation Form
This form is secure and encrypted. More information about secure forms and your privacy here.
|




